SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Drop in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 39,900 shares, a decrease of 32.1% from the October 31st total of 58,800 shares. Based on an average trading volume of 74,700 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company’s shares are sold short.

Hedge Funds Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 7.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SABS. Oppenheimer reissued an “outperform” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Craig Hallum started coverage on SAB Biotherapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target on the stock. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Stock Performance

SABS traded down $0.03 during trading on Friday, reaching $2.92. 56,852 shares of the stock traded hands, compared to its average volume of 75,648. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. The stock’s 50-day moving average is $2.99 and its 200 day moving average is $2.90. SAB Biotherapeutics has a 12 month low of $2.16 and a 12 month high of $9.72.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. On average, equities analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.